Genomic landscape of non-small-cell lung cancer in smokers and never-smokers

By Niruthika Sritharan. Thorax, 2013

998 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/9c7577d1fb0ed78e0c5d608057a2e8f4e32aa5bd

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Pulmonary and Respiratory Medicine

Citations in the corpus

ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. (2019, background): “Tumours positive for HPV and smoking-associated cancers have been suggested to harbour higher TMB in comparison with HPV-negative or nonsmoking counterparts, independently from MSI status [72, 87, 88], although the influence of HPV on TMB is still debated [89].”
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. (2015, background): “…cigarette smokers display a preponderance of C > A transversions and significantly more copy number gains and mutations compared with nonsmokers (Govindan et al., 2012; Huang et al., 2011; Pleasance et al., 2010), while colorectal cancers with endogenous mismatch repair deficiency exhibit an…”
Mutational signatures associated with tobacco smoking in human cancer (2016, background): “…previous studies have reported that the total number of substitutions is higher in smokers compared to non-smokers in lung adenocarcinoma, mainly due to C>A substitutions ( 24, 25 ), and that mutations attributed to signatures 4 and 5 are elevated in smokers with lung adenocarcinoma ( 18 ).”
Comprehensive Analysis of Hypermutation in Human Cancer (2017, positive): “…those by The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC), have confirmed frequent hypermutation in melanoma (Akbani et al., 2015), lung (Govindan et al., 2012), and bladder cancer (Weinstein et al., 2014) and uncovered rare cases of hypermutation in other cancers.”
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. (2018, background): “of patients 240 759 Median age, years (range) 66 (22-92) 66 (22-93) .”